Evotec SE

  • WKN: 566480
  • ISIN: DE0005664809
  • Land: Germany

Nachricht vom 06.09.2019 | 10:59

EVOTEC TO ATTEND UPCOMING INVESTOR CONFERENCES

DGAP-News: Evotec SE / Key word(s): Conference

06.09.2019 / 10:59
The issuer is solely responsible for the content of this announcement.


Hamburg, Germany, 06 September 2019:

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that its management will be presenting at and attending the following upcoming conferences:
 

J.P. Morgan Cazenove Pan-European Small/Mid Cap Conference, London, UK

- Date: Wednesday, 11 September 2019

- Venue: London, UK

- Attendee: Enno Spillner, Chief Financial Officer


Bank of America Merrill Lynch Global Healthcare Conference 2019, London, UK

- Date: Wednesday, 18 September 2019,
           
Presentation: 18 September 2019, 4.25 pm BST

- Venue: London, UK

- Attendee: Werner Lanthaler, Chief Executive Officer


Baader Investment Conference, Munich, Germany

- Date: Monday, 23 September 2019,
           
Presentation: 23 September 2019, 5.15 pm CEST

- Venue: Munich, Germany

- Attendee: Enno Spillner, Chief Financial Officer

 

Berenberg and Goldman Sachs Eighth German Corporate Conference, Munich, Germany

- Date: Tuesday, 24 September 2019,
           
Presentation: 24 September 2019, 2.30 pm CEST

- Venue: Munich, Germany

- Attendee: Enno Spillner, Chief Financial Officer


Ladenburg Thalmann Healthcare Conference, New York, NY, USA

- Date: Tuesday, 24 September 2019,
           
Presentation: 24 September 2019, 10.30 am EDT

- Venue: New York, NY, USA

- Attendee: Dr Werner Lanthaler, Chief Executive Officer


2019 Cantor Global Healthcare Conference, New York, NY, USA

- Date: Wednesday, 02 October 2019,
           
Presentation: 02 October 2019, 3.00 pm EDT

- Venue: New York, NY, USA

- Attendee: Dr Werner Lanthaler, Chief Executive Officer

 

ABOUT EVOTEC SE
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide and our more than 2,800 employees provide the highest quality
stand-alone and integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. On this basis, Evotec has built a broad and deep pipeline of approx. 100 co-owned product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term alliances with partners including Bayer, Boehringer Ingelheim, Celgene, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional information please go to www.evotec.com and follow us on Twitter @Evotec.
 

FORWARD LOOKING STATEMENTS
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.


Contact Evotec SE:
Gabriele Hansen, VP Corporate Communications, Marketing & Investor Relations, Phone: +49.(0)40.56081-255, gabriele.hansen@evotec.com
 



06.09.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC-Fokusbox

Expedeon AG mit attraktiver Produktpipeline

Durch die konsequente Fortsetzung der „Grow, Buy & Build“-Strategie hat die im Bereich der Entwicklung und Vermarktung von DNA-Technologien, Proteomik- und Antikörper-Konjugations-Anwendungen tätige Expedeon AG das Umsatzniveau angehoben und auf operativer Ergebnisebene zugleich den Break-Even nachhaltig überschritten. Für die kommenden Perioden ist der Ausbau der Umsatzerlöse mit den bestehenden Produkten geplant. Darüber hinaus verfügt die Expedeon AG über eine attraktive Produktpipeline mit hohem Umsatzpotenzial. Unser Kursziel liegt bei 3,20 € je Aktie. Das Rating lautet KAUFEN.

News im Fokus

Wirecard AG startet Aktienrückkaufprogramm in Höhe von bis zu 200 Mio. EUR

18. Oktober 2019, 16:04

Aktuelle Research-Studie

ad pepper media International N.V.

Original-Research: ad pepper media International N.V. (von First Berlin Equity Research GmbH): Hinzufügen

18. Oktober 2019